Does platelet antiaggregant therapy lessen the severity of stroke?
Data from the Aspirin in Transient Ischemic Attack (AITIA) study, an ongoing study of two platelet antiaggregant drugs, and other published therapeutic trials were reviewed to determine whether the severity of stroke is reduced in patients taking platelet antiaggregants. Data from three of four studies suggest that strokes in treated patients are less severe than those in untreated patients. Further studies evaluating platelet antiaggregant therapy should include assessment of the severity as well as the incidence of stroke.
D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000503:physiopathology; D010974:Platelet Aggregation / Q000187:drug effects*; D011446:Prospective Studies; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000494:pharmacology / Q000627:therapeutic use*
D001241:Aspirin; D013442:Sulfinpyrazone